Areas of research

TRANSLATIONAL

Our translational oncology research bridges the gap between laboratory discoveries and clinical application. By integrating insights from molecular biology, genetics, and pharmacology, we aim to transform scientific findings into effective, targeted therapies. This approach accelerates the development of personalised treatment strategies, enabling faster delivery of innovative cancer therapies to patients. Our team collaborates closely with clinical partners to ensure that promising laboratory results are rapidly and safely translated into real-world cancer care solutions.

Immune-oncology

Our immuno-oncology research focuses on harnessing the body’s own immune system to recognise and eliminate cancer cells. Through the study of immune mechanisms and tumour microenvironments, we develop and test novel immunotherapies — including checkpoint inhibitors, cellular therapies, and cancer vaccines. Our goal is to enhance the immune system’s ability to target a wide range of cancers, improve patient outcomes, and reduce treatment resistance. This research is at the forefront of precision medicine and represents a paradigm shift in how cancer is treated.

Solid tumors

We conduct extensive research on a variety of solid tumours, with a particular focus on breast, lung, colon cancer, and melanoma. Our work spans molecular characterisation, biomarker discovery, and clinical trial design to better understand tumour biology and identify the most effective therapeutic interventions. By studying these high-burden cancers, we aim to improve diagnostic accuracy, advance treatment efficacy, and contribute to long-term survival and quality of life for patients.

Multi-phase studies

Our clinical research portfolio includes early-phase (I & II) exploratory studies, as well as late-phase (III & IV) confirmatory trials. Early-phase trials focus on assessing safety, dosage, and preliminary efficacy of novel compounds, laying the foundation for future therapeutic breakthroughs. Phase III studies validate these findings in larger populations, while Phase IV trials evaluate long-term safety and real-world effectiveness post-approval. Through rigorous clinical research, we ensure that new cancer treatments are evidence-based, effective, and aligned with patient needs.

Our multi-disciplinary teams include:

  • Plastic surgeons
  • Dermatologist
  • Cardiothoracic surgeons
  • Pathology
  • Specialist surgeons
  • Supportive care
  • University of Pretoria

Team Members

  • Prof Rapoport
  • Teresa Smit
  • Prof Anderson
  • Prof Helen Steel
  • Prof Theresa Rossouw
  • Prof Carol Benn
  • Dr Daniel van Tonder

Research Infrastructure & Expertise

Fully Equipped Facility

Our modern facility is purpose-built for clinical research, featuring on-site laboratories, infusion suites, consultation rooms, and advanced diagnostic equipment. Every aspect of the environment is designed to uphold the highest standards of safety, comfort, and data accuracy.

Experienced Clinical Trial Team

Our multidisciplinary team includes oncologists, clinical researchers, study coordinators, pharmacists, and regulatory specialists — each bringing years of experience in oncology trials. Together, they ensure seamless execution, from protocol development to study completion, always prioritising scientific integrity and patient wellbeing.

Practice Setting, Equipment & Facility

Operating within a specialised oncology practice, our research environment integrates patient care with research excellence. Equipped with cutting-edge diagnostic tools and real-time monitoring systems, our site complies with international Good Clinical Practice (GCP) standards and is fully prepared for sponsor audits and inspections.

20+ Years of Experience

With over two decades of oncology research expertise, our team has played a role in landmark studies that have shaped current treatment standards. This depth of experience allows us to manage complex clinical trials efficiently and deliver consistently high-quality results for both sponsors and patients.

Countrywide Referral Base

We collaborate with a robust national network of hospitals, clinics, and oncology specialists, providing access to a diverse and representative patient population. This countrywide referral base supports efficient recruitment and ensures our studies reflect real-world clinical diversity.